Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
NCT07228026
This study is recruiting at 13 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
This study incorporates objectives directed at two subject cohorts: Uncontrolled Adult and Pediatric Asthma Subjects: To demonstrate a statistically significant and clinically meaningful decline in Point Of Care (POC) FeNO as measured by the fenoTRACK device, after an approximately 2-week course of corticosteroid therapy in adults and children with non-steroid treated uncontrolled asthma.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 5 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Biometry Inc
- Last updated on ClinicalTrials.gov
- June 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Bensch Clinical Research LLC · Stockton, CA
Florida · 1
- AllerVie Clinical Research · Panama City, FL
Georgia · 1
- AllerVie Clinical Research · Columbus, GA
Maine · 1
- Paul A Shapero MD · Bangor, ME
Maryland · 2
- AllerVie Clinical Research · Ellicott City, MD
- AllerVie Clinical Research · Glenn Dale, MD
Nebraska · 1
- Nebraska Medical Research Institute, Inc. · Bellevue, NE
North Carolina · 1
- Allergy Partners Clinical Research · Asheville, NC
Ohio · 1
- Toledo Institute of Clinical Research Inc · Toledo, OH
Texas · 3
- Orion Clinical Research · Austin, TX
- Pharmaceutical Research & Consulting, Inc. · Dallas, TX
- Western Sky Medical Research · El Paso, TX
Wisconsin · 1
- Allergy, Asthma & Sinus Center, S.C. · Greenfield, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.